Description: United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Home Page: www.unither.com
1000 Spring Street
Silver Spring,
MD
20910
United States
Phone:
301 608 9292
Officers
Name | Title |
---|---|
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. | Founder, Chairman & CEO |
Mr. Michael I. Benkowitz | President & COO |
Mr. James C. Edgemond | CFO & Treasurer |
Mr. Paul A. Mahon J.D. | Executive VP, General Counsel & Corporate Secretary |
Mr. Dewey Steadman C.F.A. | Head of Investor Relations |
Ms. Holly Hobson | Associate Vice President of Human Resources |
Kevin T. Gray | Senior Vice President of Strategic Operations & Logistics |
Mr. Patrick Poisson | Executive VP of Technical Operations |
Dr. Leigh Peterson | Executive Vice President of Product Development & Xenotransplantation |
Mr. Gil Golden | Senior VP & Chief Medical Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Biotechnology |
GIC Sub-Industry: | Biotechnology |
Forward PE: | 13.5318 |
---|---|
Trailing PE: | 16.2326 |
Price-to-Book MRQ: | 2.7034 |
Price-to-Sales TTM: | 5.7686 |
IPO Date: | |
Fiscal Year End: | December |
Full Time Employees: | 1168 |